Article

Diabetes Dialogue: Barriers & Inequities to Care, with Jasmine Gonzalvo, PharmD

In the third special edition episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives from ADA 2022, Jasmine Gonzalvo, PharmD, joins hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss prevailing barriers in diabetes management, including access to new pharmacologic agents as well as newer diabetes technologies.

One of the prevailing themes at the American Diabetes Association (ADA) 82nd Scientific Sessions was addressing inequities in diabetes management and the impact they have on care and quality of life in patients with diabetes. With dozens of sessions and abstracts dedicated to inequities based on race/ethnicity, gender, socioeconomic status, and more, the emphasis on breaking down barriers in diabetes care has never been more evident than at ADA 2022.

Within one of the many symposiums taking place at the meeting, Jasmine Gonzalvo, PharmD, led a discussion on barriers and solutions to accessing diabetes technology for underserved populations. The director of the Center for Health Equity and Innovation at the Purdue University College of Pharmacy, Gonzalvo’s role provides her with a unique perspective from the frontline of driving change in her own health system and beyond.

In the third special edition episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives from ADA 2022, Gonzalvo joins hosts Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP, and Natalie Bellini, DNP, FNP-BC, to discuss prevailing barriers in diabetes management, including access to new pharmacologic agents as well as newer diabetes technologies.

Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives is available in an audio-only format on Spotify and Apple Podcasts.

Related Videos
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
4 experts are featured in this series.
4 experts are featured in this series.
© 2024 MJH Life Sciences

All rights reserved.